SAN DIEGO, July 23, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...

Preliminary results of a first-in-human phase 1b (aCCeleR8-001) study of S-531011, a humanized anti-CCR8 monoclonal antibody, in patients with advanced solid tumors. Efficacy and safety of ozuriftamab ...

Biologists discovered that a mutation in the ROR2 gene is linked to beak size reduction in numerous breeds of domestic pigeons. Surprisingly, different mutations in ROR2 also underlie a human disorder ...

What is new about the study? Throughout life we all develop lesions in the cartilage. For many people, especially after a certain age, cartilage loss becomes so bad that the bones grind against each ...

Western blots can often be overlooked as a commonplace research tool in proteomics, but there have been continual updates and progress in the technical development of the western blot and the list of ...

Ozuriftamab vedotin, the Company’s conditionally and reversibly active antibody drug conjugate directed against ROR2, has shown promising clinical activity with a manageable safety profile in ...